机构投资者推高了AbbVie股价，强劲的盈利和上调的指引推动了“中度买入”评级。 Institutional investors boosted AbbVie shares as strong earnings and raised guidance fueled a "Moderate Buy" rating.

机构投资者增加了在AbbVie公司的股份,尼古拉斯财富有限公司、Stonbrook私人公司和Traub资本管理有限公司在第二季度都增加了股份。 Institutional investors increased their stake in AbbVie Inc., with Nicholas Wealth LLC, Stonebrook Private Inc., and Traub Capital Management LLC all adding shares in the second quarter. 据该公司报告,Q3收入强劲,为186 EPS,估计损失为0.09美元,收入逐年增长9.1%,达157.8亿美元。 The company reported strong Q3 earnings of $1.86 EPS, beating estimates by $0.09, and revenue rose 9.1% year-over-year to $15.78 billion. AbbVie将其全年2025年EPS指南提高到3.320-3.360美元,并将其季度红利提高到1.73美元,收益率为3.0%。 AbbVie raised its full-year 2025 EPS guidance to $3.320–3.360 and increased its quarterly dividend to $1.73, yielding 3.0%. 股价为233.83美元,市场上限为413.27亿美元。 股价为240.14美元,目标价格为240.14美元。 The stock, trading at $233.83 with a market cap of $413.27 billion, has a consensus "Moderate Buy" rating and a target price of $240.14.